Catalyst Dossier · compiled by CeliA 🧫
Roche Holding AG (RHHBY)
Biotechnology · market cap $316.4B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-08 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Roche Holding AG (RHHBY) is a large-cap Swiss biotechnology and pharmaceutical company with approximately 103,249 employees and a market capitalization of roughly $316 billion. The company operates a broad, mature pipeline spanning oncology, neurology, immunology, and rare disease, with lead emerging assets including RO7239361 (Phase 3, Duchenne Muscular Dystrophy) and RO7204239 (Phase 3, Obesity). Seven analysts carry a consensus buy rating with a mean price target of approximately $56.66.
The catalyst path
- 2026-10-08 (est.)Phase 2 · Axitinibimp 7/10
- 2026-10-16 (est.)Phase 2 · 89Zr-Df-IAB22M2Cimp 7/10
- 2026-11-19 (est.)Phase 2 · RO7269162imp 7/10
- 2026-11-30NDA Filingimp 8/10
- 2026-12-01 (est.)Phase 2 · Tocilizumab 20 MG/MLimp 7/10
- 2026-12-15 (est.)Phase 2 · Association atezolizumab + BDB001 + RTimp 7/10
- 2026-12-18 (est.)NDA Filingimp 8/10
- 2026-12-20 (est.)Phase 3 · Alectinibimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Dendritic cell vaccination | Phase 2 | Malignant Pleural Mesothelioma |
| erlotinib HCl | Phase 2 | Non-Small Cell Lung Cancer |
| Azathioprine or Mycophenolate mofetil | Phase 2 | Bullous Pemphigoid |
| Trastuzumab, Docetaxel | Phase 2 | Breast Cancer |
| RO7239361 | Phase 3 | Duchenne Muscular Dystrophy |
| MabThera | Phase 3 | Humoral Rejection in Kidney Transplantation |
| RO7204239 | Phase 3 | Obesity |
| trastuzumab (Herceptin®) | Phase 3 | Breast Cancer |
| mycophenolate mofetil [CellCept] | Phase 3 | Myasthenia Gravis Generalised |
| Lenvatinib | Phase 3 | Unresectable Hepatocellular Carcinoma |
| Eculizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| Dual Integrin Antagonist | Phase 2 | Asthma |
| RO4917523 1.5 mg | Phase 2 | Major Depressive Disorder |
| 5 FU | Phase 3 | Neoplasms |
| Atezolizumab Cohort 7 | Phase 2 | Solid Tumors |
| boceprevir | Phase 2 | Hepatitis C, Chronic |
| Abemaciclib | Phase 3 | Ovarian Cancer |
| Intravitreal Ranibizumab 0.5 mg Injection | Phase 3 | Diabetic Macular Edema |
| Treatment of physician's choice | Phase 3 | Breast Cancer |
| Mesna | Phase 2 | Lymphoma |
Price & technical context
3-month
+8.9%
6-month
+11.9%
12-month
+31.5%
52-wk range
$39.59–$60.58
vs 50-day MA
-0.9%
vs 200-day MA
+2.2%
Realized vol
38.1%
Max drawdown
-21.8%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RHHBY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.